Evidence mapPaperPMID 41900975Full record

ArticleLife (Basel, Switzerland)2026

Modulating Vimentin: A Systems-Level Therapeutic Strategy for Sepsis and Complex Diseases.

Ruihuan Chen, Jianping Wu, Daniel Jafari, Annica K B Gad

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruihuan ChenAluda Pharmaceuticals, Inc., Union City, CA 94587, USA.ORCID 0000-0002-0641-2132
Jianping WuLaboratory Animal Center, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210029, China.
Daniel JafariNorthwell, New Hyde Park, NY 11040, USA.ORCID 0000-0002-8217-5407
Annica K B GadDepartment of Oncology-Pathology, Karolinska Institutet, 171 64 Solna, Sweden.ORCID 0000-0002-1098-9129

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis remains a leading global health challenge, characterized by high mortality and a persistent lack of disease-modifying therapies. Despite decades of investment, therapeutic progress has been constrained by reductionist strategies that target isolated pathogenic components. This perspective argues that these failures reflect a fundamental mischaracterization of sepsis-not as a disorder of discrete pathways, but as the collapse of complex biological systems in which normally coordinated processes become desynchronized. We identify the intermediate filament protein vimentin as a determinant of system fate governing the transition from adaptive host defense to pathological breakdown. Acting as a context-dependent network integrator and signal amplifier, vimentin coordinates antagonistic cellular programs by integrating biochemical and biophysical cues across immune, vascular, and metabolic systems. Under physiological stress, this coordination enables the orderly activation and resolution of inflammatory and suppressive responses required for pathogen control and restoration of homeostasis. In sepsis, persistent or excessive insults drive vimentin-mediated overactivation, uncoupling these programs and propagating systems-level instability that culminates in organ dysfunction. By integrating mechanistic, preclinical, and emerging clinical evidence, this perspective proposes vimentin modulation as a clinically translatable, systems-oriented strategy aimed at realigning host response networks to address the dynamic, opposing pathologies of sepsis that have eluded current therapies.

Indexed as

complex systemdisease-modifying therapyhost response dysregulationnetwork coordinationsepsissystems biologytherapeutic strategyvimentin

Identifiers

PMID41900975
PMCPMC13027886

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.